


AnteoBind™ market opportunities & partnership landscape

Life Sciences Business | Investor Presentation

22 October 2026





Disclaimer

IMPORTANT INFORMATION

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX: ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Past performance is not indicative of future performance.

FORWARD-LOOKING STATEMENTS

The presentation may contain certain "forward-looking statements". Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", "aim", "estimate", "target", "anticipate", "believe", "continue", "objectives", "outlook", "guidance" or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.

NOT AN OFFER OF SECURITIES


This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.

This presentation has been approved for release to the ASX by the Board of AnteoTech.

AnteoBind™ NXT, Anteo X®, Anteo S™ and Ultranode® are trademarks of AnteoTech. The use of registered and pending trademark symbols throughout the presentation is implied. All \$ quoted are AUD unless otherwise stated.



Who We Are



Chemical and Advanced Material solutions

For life sciences and next-generation batteries

One
proprietary
chemical platform

Two
global markets



Life
Sciences



Battery
Technologies

Multiple
opportunities



Established in 2000



Publicly listed company
ASX: ADO (in 2006)



Established commercial supply
relationships to global diagnostic
customers



Laboratories, testing
facilities & Pilot Plant



Capital Structure and Corporate Overview


Market Capitalisation

\$49 m
as at 19 October 2026

Capital Structure (as at 19 October 2026)

Cash in Bank	\$11.2 million total as at 30 June 2026 (including Term Deposits)
Shares	3,265.1 million
Unlisted Options	233.5 million (7% expire in 2026, 65% in 2028). Employee/Director options 39%
Top 20 Holders	Hold 20% of shares

Share Price – 6 months to 19 October 2026



Source: <https://www.asx.com.au/markets/company/ADO>

Directors



Glenda McLoughlin

Non-Executive Chair
Investment Banker with Morgan Stanley, Credit Suisse and Barclays. Commercial Advisor and ASX Founder. Energy and Infrastructure sector expertise.



Dr. Geoff Cumming

Non-Executive Director
Career spanning research to sales and marketing and Executive roles with Roche Also on INOVIQ Ltd (IIQ) Board. Biotechnology and Healthcare sector expertise.



Merrill Gray

Managing Director/CEO
ASX Founder and MD/CEO. Energy incl. Battery (CAM (LFP/LMFP), Graphite and Recycling) plus Hydrogen and Renewables experience.



AnteoTech's Life Sciences Products

Early revenue business, operating in target markets which have ~US\$90 billion in sales annually¹

Established and growing business



- Advanced chemical and materials solutions business
- Two businesses: Life Sciences and Advanced Battery Technologies
- Headquartered in Brisbane, Australia


Proprietary technology



AnteoBind™ Product Portfolio

- **AnteoBind™** – Proprietary surface chemistry technology that binds antibodies and other biomolecules to diagnostic surfaces.
- **AnteoBind™ NXT** – Next-generation technology that improves assay performance and manufacturing efficiency.
- **Multiplex Activation Kit** - Optimised particle activation in multiplex diagnostic applications.
- **AnteoBind™ ELISA Reagents and Plates** - Reagents and activated microplates for ELISA applications.
- **Biosensor** – Surface chemistry technology for electrodes and other specialised diagnostic surfaces.

Innovating for the next generation of diagnostics



AnteoBind delivers substantial improvements to In Vitro Diagnostics (IVD) developers


- Up to **90% reduction** in antibody requirements for assays
- Up to 45 times **higher signal** compared to traditional chemistries
- **Stable coating** for >12 months
- **Enhanced compatibility and specificity**
- **Reduced wastage and shortened development timelines**

Global Commercialisation Strategy

Regional commercial strategy and market priorities.

Source: ASX release, 10 June 2025, Strategic Review Outcomes
TIQ: Trade and Investment Queensland. JDA: Joint development agreement.

● Existing markets ● New opportunities



USA

Strategy

- Grow our customer base
- Attract strategic partners

Life Sciences

- Point-of-care diagnostics, CLIA and ELISA markets

Batteries

- **Ultranode™ 95**: defence and security drones
- Manned & unmanned aerial systems (UAS)
- Carbon nanotube JDA (SiMRAX)



Europe

Strategy

- Grow customer base
- Attract strategic partners

Life Sciences

- Global life sciences company engagement: lateral flow, CLIA and ELISA

Batteries

- **WYON Ultranode™ 70** evaluation and validation
- New customers



India

Strategy

- Sales growth
- Secure strategic partnerships using a profit repatriation model

Life Sciences

- Expand **Serum Institute of India** relationship and secure similar customers
- Work with Austrade and Trade and Investment Queensland (TIQ)

Batteries

- Ultranode™ and performance additives: e-mobility and wearables
- Large-scale battery material manufacturer supply
- Joint product development (JDA)



South Korea & Japan

Strategy

- Expand our customer base and sales
- Attract strategic partners

Life Sciences


- Distributors supporting growth
- Austrade and TIQ support

Batteries

- Market entry
- Distributors supporting growth
- Austrade and TIQ support


One surface chemistry, four detection platforms

Coordination bonding for antibody and protein immobilisation in IVD assays




Lateral flow

Antibody conjugation to latex for rapid tests




Chemiluminescence

Magnetic bead conjugation for CLIA immunoassays



AnteoBind™



ELISA

Microplate activation for antibody and antigen coating



Biosensors

Biomolecule immobilisation on sensor surfaces




AnteoTech's commercial position today in the Life Sciences market

- **Established Commercial Supply/Revenues**
Five-year take-or-pay US\$ 1.8 million supply agreement with the Serum Institute of India signed in mid 2024.
- **Growing International Distribution Network**
Established distributor arrangement, including Cosmo Bio in Japan and KOMA in South Korea
- **Paid Development Collaboration**
CLIA development program with a major global Life Sciences company in progress
- **Expanding Customer Pipeline**
Customer engagement and sample evaluations underway with Sales Qualified Leads (SQL) across four diagnostic platforms.

Where we are heading ...

Lateral Flow: Broad Customer Base Across Global Diagnostics Markets



AnteoBind™ supports antibody conjugation to particles used in rapid diagnostic tests.

GLOBAL MARKET SIZE (2024)

US\$15.5B

DISCUSSIONS UNDERWAY (SQL)

17


Across manufacturers, developers and research organisations

ANTEOBIND™ APPLICATION

Latex & Gold

Antibody conjugation for multiple particle types for conjugation in rapid diagnostic tests

IMMUNOASSAY MARKET BY PLATFORM (US\$B: 2024)




GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER

- 2 Large-Scale Manufacturers**
Indian operations of a global IVD group and contract development/manufacturing company's in Spain and the UK
- 5 Established Diagnostics Companies**
Diagnostic test manufacturers across Canada, France, Spain, the United States and India
- 8 Emerging and Specialist Developers**
Developers of rapid diagnostic technologies, including companies in Finland and India
- 2 Academic and Research Partners**
Australian university collaboration and Indian national research institute

Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates shown in US dollars for 2024. Market figures represent broader diagnostic segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may be represented across multiple application categories. Names withheld.

CLIA: Engaging with Global Diagnostic Manufacturers



AnteoBind™ supports antibody conjugation to magnetic beads used in automated chemiluminescence immunoassays (CLIA).

GLOBAL MARKET SIZE (2024)

US\$13B

Estimated 6% CAGR to 2029*

DISCUSSIONS UNDERWAY (SQL)

9


Including four major global IVD manufacturers

ANTEOBIND™ APPLICATION

Magnetic Beads

Antibody conjugation for automated CLIA assays

GLOBAL DIAGNOSTIC MARKET SEGMENTS: (US\$B, 2024)



GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER

- 4 Major Global IVD Manufacturers**
Diagnostic analyser manufacturers headquartered in Japan, the United States, Spain and Italy
- 1 Multinational Diagnostics Group**
Indian operations of a global diagnostics manufacturer
- 2 Established IVD Manufacturers**
Canadian multi-platform diagnostic test manufacturer and established Indian IVD company
- 2 Specialist and Emerging Developers**
Haemostasis diagnostics specialist and Indian multi-platform assay developer

Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates in US dollars for 2024. Market figures represent broader diagnostic segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld.

ELISA: Expanding Opportunities in Diagnostic Microplates



AnteoBind™ surface chemistry supports antibody and antigen immobilisation on microplates used in ELISA diagnostic assays.

GLOBAL MARKET SIZE (2024)

US\$21B

Estimated 5% CAGR to 2029*

DISCUSSIONS UNDERWAY (SQL)

2

Both organisations active across multiple diagnostic platforms

ANTEOBIND™ APPLICATIONS

Microplates

Surface activation for antibody and antigen immobilisation

GLOBAL DIAGNOSTIC MARKET SEGMENTS: (US\$B, 2024)




GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER

- 1 Established IVD manufacturer**
Diagnostic manufacturer supplying rapid tests, ELISA and CLIA kits
- 1 Emerging Diagnostic Developer**
Developer of diagnostic assays across ELISA, lateral flow and other platforms

Commercialisation: This is a recent offering, still at prototyping/early market entry stage, that would expand AnteoBind™ applications into ELISA microplates.

Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates in US dollars for 2024. Figures represent broader diagnostic market segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld.

Biosensors: Expanding AnteoBind™ into Emerging Diagnostic Applications



AnteoBind™ supports the immobilisation of biomolecules on sensor surfaces for potential biosensor applications.

GLOBAL MARKET SIZE (2025)

US\$34.5B

Estimated 9.5% CAGR to 2030 across all biosensor applications*

DISCUSSIONS UNDERWAY (SQL)

3


Research and technology organisations identified

ANTEOBIND™ APPLICATION

Sensor Surfaces

Biomolecule immobilisation for biosensor development

GLOBAL BIOSENSORS MARKET: 2025 TO 2030 (US\$B)



POTENTIAL COLLABORATION PARTNERS

- 1 Australian Biosensor Research Network**
Participating in a national research hub connecting six universities and more than 20 industry partners (MOBIUS)
- 1 Government Research Institute**
Indian pharmaceutical research institute with activities spanning biosensors and lateral flow diagnostics (NIPER)
- 1 Life Sciences Technology Provider**
Indian company specialising in genomics and cell biology technologies

Source: MarketsandMarkets, Biosensors Market (July 2025). Market estimates cover all biosensor applications, including wearables and glucose monitoring, and do not represent AnteoTech's directly addressable market. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld.

Multiple Applications, Expanding Commercial Opportunities

One proprietary surface chemistry platform and customer engagement globally across established and emerging diagnostic markets and applications.

LATERAL FLOW

17

Latex and gold particle conjugation for rapid diagnostic tests

CLIA

9

Magnetic bead activation for automated immunoassays

ELISA

2

Activated microplates for antibody and antigen immobilisation

BIOSENSORS

3

Biomolecule immobilisation on sensor surfaces

COMMERCIALISATION PRIORITIES

Expansion in established Diagnostic Markets

Progress customer sample evaluations and pursue commercial supply agreements across Lateral flow, CLIA and ELISA.




Emerging Applications

Explore opportunities to integrate AnteoBind™ into biosensors and next-generation diagnostic platforms.

Expanding Market Reach Through Potential Life Sciences Partnerships

Supply partnerships can bring AnteoBind™ to large and established IVD customer bases



PARTICLE MANUFACTURERS | 3 potential partners are being engaged with



Global OEM reagent manufacturer
Europe

Supplies gold colloid, conjugates and IVD reagents to lateral flow and immunoassay developers

Fit **Lateral flow** · **CLIA** · **ELISA**



Life sciences multinational
Europe

Supplies microspheres and magnetic beads to IVD manufacturers

Fit **CLIA** · **Lateral flow** · **Multiplex**



Microsphere specialist
China

Potential supplier of magnetic and fluorescent microspheres for CLIA and biopharma at production scale

Fit **CLIA** · **Multiplex** · **Bioseparation**

FURTHER PARTNERSHIP CHANNELS

4

Multiplex bead assays / LUMINEX

Diagnostics, pharmaceutical and vaccine companies across India, Europe

3

Bioseparation

European manufacturers of microspheres, agarose-bead and separation technologies

2

Fluorescence immunoassay

IVD assay developer and vaccine manufacturer in India


1

Microfluidics

Indian developer of Point-of-care microfluidic diagnostic devices

Expanding AnteoBind™ across the Diagnostics Value Chain

Moving beyond reagent supply to integrate and embed AnteoBind™ into assays and new platforms



1 Partner with particle & plate makers

Co-develop AnteoBind™-activated particles and plates

- Supply pre-activated particles and plates to IVD manufacturers
- Access established customer bases through partners
- Secure co-branded, white-label or recurring supply agreements

3 particle manufacturers already identified

2 Collaborate with diagnostic developers

Embed AnteoBind™ during new diagnostic platform development

- Incorporate AnteoBind early in assay & platform development
- Support long term adoption through customer validation

Early-stage developers identified across platforms



THANK YOU

Contact:

Merrill Gray

investors@anteotech.com

+61 (07) 3219 0085

www.anteotech.com

